Clinical trials: Healthy Young Subjects
Influenza
Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)
The aim of the present dose ranging study is to evaluate the safety, tolerability and immunogenicity of two doses of twelve different formulations of a Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine, adjuvanted with…
- Trial name
- NCT00812019
- Testing
- Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_0%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_25%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_50%MF59
- Where
- 2 sites in United States, Germany
- Volunteers
- 753 people, healthy volunteers welcome
- Sponsor
- Seqirus
Healthy
AZD0837 Extended Release (ER) Japan Study
This phase I study will evaluate safety and tolerability after repeated doses of AZD0837.
- Trial name
- ER J ph I (NCT00904800)
- Testing
- AZD0837
- Where
- Japan
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Cardiovascular Diseases
Safety of Single Intravenous Administration of S95010 in Human Healthy Volunteers
The purpose of the study is to assess, the safety and tolerability of single ascending doses of S 95010 and to assess the pharmacokinetics (PK) of S 95010.
- Trial name
- NCT03494712
- Testing
- S 95010
- Where
- Belgium
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Institut de Recherches Internationales Servier
Healthy
Oxidative Stress as an Acute Exercise-induced Mechanism of Stem and Progenitor Cell Mobilization
It is already known from literature that exercise mobilizes stem and progenitor cells into the peripheral blood. However, the exact mechanisms thereof remain to be fully elucidated.
- Trial name
- EISMO (NCT03747913)
- Testing
- Antioxidative supplementation
- Where
- Switzerland
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Swiss Federal Institute of Technology
Thrombosis
A Study to Investigate Biomarkers After Single Doses of Anticoagulants in Healthy Young Male and Healthy Elderly Participants (MK-0000-216 AM1)
This is a study to investigate biomarkers after single oral doses of the anticoagulant agents dabigatran etexilate and rivaroxaban in healthy young male subjects and in healthy elderly subjects.
- Trial name
- NCT01379300
- Testing
- dabigatran etexilate, rivaroxaban
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy Volunteers
Safety, Tolerability, and Pharmacokinetics Study of ATH-1020
This Phase 1 randomized, placebo-controlled, double-blinded, first-in-human study will evaluate safety, tolerability, and pharmacokinetics of single and multiple ascending doses of ATH-1020 in healthy young and elderly subjects.
- Trial name
- NCT05169671
- Testing
- ATH-1020
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- LeonaBio
Alzheimer's Disease
Safety, Pharmacokinetics and Pharmacodynamics Study of Treatment With CHF 5074 in Healthy Young Male Subjects
The purpose of this study is to evaluate the safety and tolerability of single oral doses of CHF 5074 in young healthy male volunteers.
- Trial name
- CT01 (NCT00954252)
- Testing
- CHF 5074
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- CERESPIR
Pharmacokinetics, Healthy Subjects
To Evaluate the Blood and Urine Concentration and the Safety and Tolerability of Increasing Repeated Doses of Mirabegron (YM178) OCAS in Healthy Young and Elderly Males and Healthy Young and Elderly Females
The study aimed to compare age and gender differences for increasing doses of mirabegron when given to healthy young and elderly males and healthy young and elderly females.
- Trial name
- NCT01478503
- Testing
- mirabegron OCAS
- Where
- 2 sites in Netherlands
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Non-24-Hour-Sleep-Wake Disorder
Open Label Study to Assess the Absolute Bioavailability of Tasimelteon (HETLIOZ™)
Hetlioz™ (tasimelteon) is used in the treatment of Non-24-Hour-Sleep-Wake Disorder (Non-24). Non-24 is very common in people who are totally blind because light can not reset their body clock.
- Trial name
- NCT02130999
- Testing
- tasimelteon 20 mg capsule, tasimelteon 2 mg I.V.
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Vanda Pharmaceuticals
Gram-negative Bacterial Infection
Safety, Pharmacokinetics (PK) and Tolerability Study of a Novel Drug for Treatment of Bacterial Infections
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetic profile of an antibacterial compound for treatment of hospital acquired Gram negative infection.
- Trial name
- NCT01015014
- Testing
- AN3365
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Pfizer
Cardiovascular Diseases, Nephropathy
The Effects of Atorvastatin on the Nitric Oxide-system in Healthy Young Man
It has been documented that statin reduce mortality and morbidity in patients with cardiovascular disease. This effect can partly be related to a reduction in cholesterol levels in blood.
- Trial name
- STAR (NCT01214746)
- Testing
- Atorvastatin
- Where
- Denmark
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Regional Hospital Holstebro
Healthy Subjects
Circulating Levels of Irisin in Healthy Young Subjects
Irisin, a newly discovered myokine induced in exercise, has potential effects in stimulating adipose tissue browning, fighting obesity and diabetes.
- Trial name
- IRISSAS (NCT01986530)
- Testing
- Boost, Aerobic exercise
- Where
- Greece
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- 424 General Military Hospital
Diabetes
First in Man Study With SLV341
First in man study with single and multiple rising doses with SLV341
- Trial name
- NCT00887445
- Testing
- SLV341
- Where
- United Kingdom
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Solvay Pharmaceuticals
Healthy
Circulating Endothelium Progenitor Cells and Endogenous Oestrogen in Healthy Subjects
The purpose of this study is to determine whether the number of circulating EPC is different between healthy women and men.
- Trial name
- Oestropec (NCT00668252)
- Where
- France
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Caffeine, Biomechanics
Effects of Caffeine Ingestion on the Biomechanics of Healthy Young Subjects
Caffeine is one of the few supplements that have enough scientific evidence to state that can notably improve performance, as different remarkable organizations in the sports nutrition context have classified it as an ergogenic…
- Conditions
- Caffeine, Biomechanics, Fatigue, Injuries
- Trial name
- NCT06039358
- Testing
- Caffeine., Cellulose.
- Where
- Spain
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of Vic - Central University of Catalonia
Healthy
Effects of PRJ-205 on Performance in Trained Young Subjects
Compare a dietary supplement (PRJ-205) and placebo during 1 or 4 days on aerobic exercise performance, oxidative stress and muscle damage. The hypothesis is that supplementation with PRJ-205 improve aerobic performance
- Trial name
- NCT02726516
- Testing
- PRJ-205
- Where
- Spain
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bioiberica
Schizophrenia, Cognition Disorders
The Effect of Nicotine on Arousal, Cognition and Social Cognition in Young and Elderly Healthy Subjects.
This study in young and elderly healthy subjects will investigate the effect of nicotine on arousal, cognitive task and social cognition after acute dose administration.
- Trial name
- NCT01181934
- Testing
- A643 (nicotine)
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Chemotherapy-Induced Nausea and Vomiting
A Bioequivalence Study of 3 Formulations of Ondansetron in Healthy Adults (0869-095)(COMPLETED)
This study will assess the bioequivalence of a Merck clinical trial formulation of ondansetron compared to a U.S. and non-U.S. marketed formulation of ondansetron.
- Trial name
- NCT00971633
- Testing
- Comparator: Treatment A (Zofran, ondansetron), Comparator: Treatment B (Zofran, ondansetron), Comparator: Treatment C (Zofran, ondansetron)
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Endometriosis
A Study To Investigate How The Body Handles Multiple Doses Of PF-0243873 And To Investigate The Effect Of PF-02413873 On Sex Hormone Levels In Healthy Young Women
The study will investigate how well multiple doses of PF-02413873 are tolerated by healthy young women, how the body handles multiple doses of PF-02413873 and which effect PF-02413873 has on sex hormones in healthy young women
- Trial name
- NCT00800618
- Testing
- PF-02413873 100 mg QD, PF-02413873 1500 mg QD, PF-02413873 20 mg QD
- Where
- 4 sites in United States, Belgium
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Pfizer
Complicated Infection, Bacterial Infections
To Investigate the Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI)
This is a randomised, double-blind, 3-part study designed to investigate the safety and tolerability of ATM-AVI. The study aims to characterise the pharmacokinetics of ATM-AVI, when both drugs are administered alone (ATM or AVI)…
- Trial name
- NCT01689207
- Testing
- Avibactam (AVI), Aztreonam (ATM), combination of Aztreonam - Avibactam (ATM-AVI)
- Where
- United Kingdom
- Volunteers
- 222 people, healthy volunteers welcome
- Sponsor
- Pfizer